Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 2873 entries
View as:

Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT04407247 Org: User:
Start: 07/09/20 End: 12/31/25 Due: 12/31/26

rTMS in Improving Neuropathy in Patients With Stage I-IV Cancer Who Have Received Oxaliplatin Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03219502 Org: User:
Start: 07/10/17 End: 04/30/27 Due: 04/30/28

Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion

Phase: N/A Priority: Normal
NCT ID: NCT06184321 Org: User:
Start: 08/17/23 End: 02/02/27 Due: 02/02/28

Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00431054 Org: User:
Start: 02/28/07 End: 05/31/12 Due: 05/31/13

Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers

Phase: N/A Priority: Normal
NCT ID: NCT04870788 Org: User:
Start: 03/24/21 End: 09/30/25 Due: 09/30/26

Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03263572 Org: User:
Start: 11/29/17 End: 11/30/25 Due: 11/30/26

CEP-701 for PH-negative Myelofibrosis

Phase: N/A Priority: Normal
NCT ID: NCT00494585 Org: User:
Start: 06/30/07 End: 05/31/10 Due: 05/31/11

Phase 2 Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT07011849 Org: User:
Start: 11/01/25 End: 07/01/29 Due: 07/01/30

A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06006286 Org: User:
Start: 08/08/23 End: 11/10/23 Due: 11/10/24

A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06006273 Org: User:
Start: 08/16/23 End: 12/31/28 Due: 12/31/29

Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01582191 Org: User:
Start: 05/14/12 End: 05/31/26 Due: 05/31/27

Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02684162 Org: User:
Start: 06/22/16 End: 10/08/24 Due: 10/08/25

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00038623 Org: User:
Start: 04/30/02 End: 02/28/10 Due: 02/28/11

Use of High-Resolution Microendoscopy (HRME) in Patients With Cervical Dysplasia

Phase: N/A Priority: Normal
NCT ID: NCT02420665 Org: User:
Start: 09/23/15 End: 05/14/21 Due: 05/14/22

Evaluation of Robot-Assisted Surgery in Gynecologic Oncology

Phase: N/A Priority: Normal
NCT ID: NCT00671827 Org: User:
Start: 04/29/08 End: 12/17/20 Due: 12/17/21

Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients With Newly Diagnosed Non-melanoma Brain Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01592968 Org: User:
Start: 08/02/12 End: 09/30/25 Due: 09/30/26

A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05273554 Org: User:
Start: 08/31/22 End: 12/31/25 Due: 12/31/26

Ambulatory Cancer Pain Management: A Feasibility Study

Phase: N/A Priority: Normal
NCT ID: NCT00507351 Org: User:
Start: 07/31/06 End: 07/31/09 Due: 07/31/10

Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06940518 Org: User:
Start: 10/09/25 End: 01/19/30 Due: 01/19/31

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05042687 Org: User:
Start: 12/13/21 End: 12/31/27 Due: 12/31/28

Anderson Circulating Tumor Cell Burden (CTCB) Study

Phase: N/A Priority: Normal
NCT ID: NCT00819832 Org: User:
Start: 12/31/08 End: 05/31/10 Due: 05/31/11

Survey of the Need for Information on Fertility and Menopause-Related Treatment Effects Among HSCT Patients

Phase: N/A Priority: Normal
NCT ID: NCT00429455 Org: User:
Start: 03/31/07 End: 08/31/09 Due: 08/31/10

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT02411656 Org: User:
Start: 06/11/15 End: 12/31/28 Due: 12/31/29

Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02603887 Org: User:
Start: 07/20/16 End: 12/31/27 Due: 12/31/28

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04721132 Org: User:
Start: 02/10/21 End: 12/31/27 Due: 12/31/28